Genetic Insights into Chronic Fatigue Syndrome
Chronic fatigue syndrome, also known as myalgic encephalomyelitis (ME/CFS), is a challenging condition that has often been overlooked, with many experts dismissing it as a psychological issue for years. Despite this, some medical professionals still regard it as purely a mental health concern. However, a recent large-scale genetic study offers new biological insights.
A research initiative in the UK, named DecodeME, conducted an extensive investigation into the genetic aspects of ME/CFS. Their findings identified eight potential genetic markers linked to the illness. These results, still awaiting peer review, suggest that genetics may play a role in the risk of developing ME/CFS.
One notable genetic variant identified corresponds with chronic pain, a frequent symptom experienced by those suffering from ME/CFS, as shared by Chris Ponting, the project’s lead from the University of Edinburgh. Additionally, three of the identified markers are known to respond to viral or bacterial infections. This observation could clarify why many ME/CFS patients recall an infection before their symptoms begin and potentially explains the rise in cases following the pandemic.
The DecodeME team, comprising over 50 researchers, believes that their results solidify the biological basis of ME/CFS research. They hope this will help alleviate the stigma surrounding the condition.
Alan Carson, a neuropsychiatrist from the University of Edinburgh who did not participate in the study, remarked that this is the most extensive investigation into the genetics of CFS/ME to date.
DecodeME analyzed data from over 16,000 patients, primarily female and of European descent, ensuring that only established cases were included based on strict diagnostic criteria. Patients needed a confirmed ME/CFS diagnosis alongside a key symptom called post-exertional malaise, which refers to extreme fatigue following physical or mental exertion.
While the study revealed numerous genetic connections to ME/CFS, only eight of them were confirmed in a secondary dataset of more than 13,000 cases. A third dataset containing over 14,000 cases did not replicate the results, likely due to differing diagnostic criteria for ME/CFS.
Although these genetic markers are not exclusive to individuals with ME/CFS, they appear to have a higher prevalence among those affected by the condition. Interestingly, several of these signals are expressed in brain tissues and relate to both pain and immune responses.
The researchers suggested that medications targeting the proteins linked to these genes might help mitigate the effects of infections, thereby reducing the likelihood of developing ME/CFS. However, the implications of these findings remain unclear, and limitations in the research persist. Alena Pance, a geneticist from the University of Hertfordshire, acknowledged the study as a significant step towards understanding the illness.
Yet, Carson points out that while the findings are essential, there’s still much work to be done. He cautions that identifying a few associated genes in disorders like depression hasn’t yet led to improved treatments or clearer insights.
Nevertheless, progress is being made, particularly with the input from patients. Ponting and his team contend that their discoveries about the hereditary aspects of ME/CFS enhance the chances of developing effective treatments and place ME/CFS on par with other prevalent genetic conditions.
Sonya Chowdhury, CEO of Action for ME, expressed optimism, stating that the research transition from almost no knowledge about ME causes to having specific genetic data marks significant progress. For years, individuals suffering from ME have sought recognition, and it seems science is finally advancing in that direction.
The complete research can be accessed via preprint.
